SS-145: Chemical List of FDA Approved Drugs of 2023

[Sulstice]

This list needs to be added and appended into the network:

💉Lecanemab-irmb (Lecanemab), an amyloid beta-targeting antibody used to treat AD in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.

💊Bexagliflozin (Brenzavvy), a sodium-glucose co-transporter 2 inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus.

💊Pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor used to treat r/r mantle cell lymphoma after at least 2 lines of systemic therapy.

💊Elacestrant (Orserdu), an estrogen receptor antagonist/SERD used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

💊Daprodustat (Jesduvroq), a hypoxia-inducible factor prolyl hydroxylase inhibitor used for the treatment of anemia in patients with chronic kidney disease.

💉Velmanase alfa (Lamzede), a recombinant human lysosomal alpha-mannosidase used to treat non-neurological symptoms of mild to moderate alpha-mannosidosis.

💊Sparsentan (Filspari), an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy.

👃Zavegepant (Zavzpret), an intranasal calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine.

💊Trofinetide (Daybue), a neuroprotective analogue of glypromate, used for the treatment of Rett syndrome.

💉Retifanlimab (Zynyz), a PD-1–blocking antibody indicated for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma.

💉Rezafungin (Rezzayo), an echinocandin antifungal for the treatment of candidemia and invasive candidiasis. @Cidara Therapeutics